Trivium Point Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Trivium Point Advisory's VRTX Position: Q2 2026 in Review

Trivium Point Advisory reduced its Vertex Pharmaceuticals (VRTX) stake by 29% in Q2 2026, selling an estimated $391K and leaving 2,199 shares worth $1.09M. The position accounts for 0.1% of the portfolio, ranked #185.

Trivium Point Advisory first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $3.86M in Q1 2025. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

• Trivium Point Advisory held 2,199 shares of Vertex Pharmaceuticals worth $1.09M as of Q2 2026.
• Trivium Point Advisory sold 882 Vertex Pharmaceuticals shares in Q2 2026, an estimated $391K.
• Vertex Pharmaceuticals made up 0.1% of Trivium Point Advisory's portfolio in Q2 2026, its #185 holding.
• Trivium Point Advisory first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
• Trivium Point Advisory's Vertex Pharmaceuticals position peaked at $3.86M in Q1 2025.
• 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Trivium Point Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.